↓ Skip to main content

Sulfasalazine for ankylosing spondylitis

Overview of attention for article published in Cochrane database of systematic reviews, November 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (73rd percentile)

Mentioned by

twitter
6 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
51 Dimensions

Readers on

mendeley
93 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Sulfasalazine for ankylosing spondylitis
Published in
Cochrane database of systematic reviews, November 2014
DOI 10.1002/14651858.cd004800.pub3
Pubmed ID
Authors

Junmin Chen, Shaopeng Lin, Chao Liu

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown cause and affects mainly the spine, but can also affect other joints. Disease progression may result in loss of mobility and function. Sulfasalazine is a disease-modifying antirheumatic drug used in the treatment of AS. However, its efficacy remains unclear. This is an update of a Cochrane review first published in 2005.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 1%
Colombia 1 1%
Unknown 91 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 18 19%
Student > Master 16 17%
Researcher 11 12%
Unspecified 10 11%
Student > Doctoral Student 10 11%
Other 28 30%
Readers by discipline Count As %
Medicine and Dentistry 44 47%
Unspecified 18 19%
Nursing and Health Professions 7 8%
Psychology 7 8%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Other 12 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 November 2018.
All research outputs
#3,571,104
of 12,980,533 outputs
Outputs from Cochrane database of systematic reviews
#6,542
of 10,427 outputs
Outputs of similar age
#75,464
of 290,870 outputs
Outputs of similar age from Cochrane database of systematic reviews
#186
of 254 outputs
Altmetric has tracked 12,980,533 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 10,427 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.3. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,870 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 254 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.